We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01809574
Recruitment Status : Unknown
Verified October 2013 by Meir Medical Center.
Recruitment status was:  Recruiting
First Posted : March 12, 2013
Last Update Posted : April 9, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.

Condition or disease
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Connective Tissue Disease

Study Design

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
Study Start Date : May 2013
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : March 2016


Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included
Criteria

Inclusion Criteria:

  • Age above 18 years old
  • ILD according to ATS/ERS guidelines
  • Signed inform consent

Exclusion Criteria:

  • Previous lung surgery
  • Other significant systemic disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01809574


Contacts
Contact: David Shitrit, Dr. 097471556 davids3@clalit.org.il

Locations
Israel
Meir Medical Center Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr    09-7471556    davids3@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: David Shitrit, Dr Head of Pulmonary departmant, Meir Medical Center.
More Information

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01809574     History of Changes
Other Study ID Numbers: 225-12-MMC
First Posted: March 12, 2013    Key Record Dates
Last Update Posted: April 9, 2015
Last Verified: October 2013

Keywords provided by Meir Medical Center:
Interstitial lung disease
Idiopathic pulmonary fibrosis
Connective tissue disease

Additional relevant MeSH terms:
Fibrosis
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Connective Tissue Diseases
Pathologic Processes
Respiratory Tract Diseases